Ubs Group Ag 9 Meters Biopharma, Inc. Transaction History

Ubs Group Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$0.21 - $0.32 $3 - $4	-15 Reduced 0.01%	114,899 $25,000
Q2 2022 Aug 10, 2022	BUY	$0.26 - $0.64 $22,433 - $55,219	86,281 Added 301.33%	114,914 $30,000
Q1 2022 May 16, 2022	SELL	$0.52 - $1.0 $46,349 - $89,133	-89,133 Reduced 75.69%	28,633 $17,000
Q4 2021 Feb 14, 2022	BUY	$0.85 - $1.33 $46,468 - $72,709	54,669 Added 86.64%	117,766 $116,000
Q3 2021 Nov 15, 2021	BUY	$1.03 - $1.41 $4,940 - $6,763	4,797 Added 8.23%	63,097 $82,000
Q2 2021 Aug 13, 2021	BUY	$1.04 - $1.5 $23,691 - $34,170	22,780 Added 64.13%	58,300 $64,000
Q1 2021 May 12, 2021	SELL	$0.84 - $2.16 $33,227 - $85,443	-39,557 Reduced 52.69%	35,520 $42,000
Q4 2020 Feb 11, 2021	BUY	$0.65 - $1.11 $48,022 - $82,006	73,880 Added 6172.1%	75,077 $64,000
Q3 2020 Nov 12, 2020	BUY	$0.48 - $0.84 $574 - $1,005	1,197 New	1,197 $1,000

67.9K

Ticker NMTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,955,400
Market Cap $259K
Description
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as we...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.